BridgeMD
New treatment option for Thoracic Paravertebral Block
Official title Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain
ClinicalTrials.gov ID: NCT06165991
What this study is testing
What is GroupB:Liposomal bupivacaine and bupivacaine hydrochloride;?
GroupB:Liposomal bupivacaine and bupivacaine hydrochloride; is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for thoracic paravertebral block.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- I. Research purpose 1.1 Main Objective: To investigate the efficacy and safety of bupivacaine liposome thoracic paravertebral nerve block for postoperative analgesia after thoracoscopic lobectomy 1.2 Exploratory Objective: To investigate the noninferiority of bupivacaine liposomes in thoracic paravertebral nerve block with standard bupivacaine
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 1) Age ≥18 years old;
- 2) Patients undergoing unilateral initial thoracoscopic lobectomy under general anesthesia (TV or robot-assisted);
- 3) American Society of Anesthesiologists (ASA) Grade I - III;
- 4) Voluntarily participate in the study and sign the informed consent.
You likely can't join if
- 1) Pregnant or lactating women;
- 2) Pulmonary wedge-shaped resection;
- 3) ≥2 thoracic drainage tubes;
- 4) Abnormal liver function: ALT and/or AST\>2×ULN, or
- TBIL≥1.5×ULN;
- 5) Renal function impairment (serum creatinine \>176μmol/L), or received dialysis treatment within 28 days before surgery;
See the full eligibility criteria
- 1) Age ≥18 years old;
- 2) Patients undergoing unilateral initial thoracoscopic lobectomy under general anesthesia (TV or robot-assisted);
- 3) American Society of Anesthesiologists (ASA) Grade I - III;
- 4) Voluntarily participate in the study and sign the informed consent.
- 1) Pregnant or lactating women;
- 2) Pulmonary wedge-shaped resection;
- 3) ≥2 thoracic drainage tubes;
- 4) Abnormal liver function: ALT and/or AST\>2×ULN, or
- TBIL≥1.5×ULN;
- 5) Renal function impairment (serum creatinine \>176μmol/L), or received dialysis treatment within 28 days before surgery;
- 6) Participate in another research trial involving an investigational drug within 6 months;
- 7) A history of drug or alcohol abuse;
- 8) Long-term use of opioids (more than 3 months or more than 5 mg daily morphine equivalent per day for 1 month);
- 9) History of allergy to local anesthetics or one of the investigational drugs;
- 10) Uncontrolled mental or neurological symptoms.
The study team makes the final eligibility decision.
Where it's taking place
- Jinan, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Jinan, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.